Video

Expert Discusses How DMT Differs From Other Psychedelic Medicines

Carol Routledge, PhD, chief medical and scientific officer at Small Pharma, discusses DMT, how it differs from other psychedelic medicines, and what the future holds for DMT-assisted treatments.

Carol Routledge, PhD, chief medical and scientific officer at Small Pharma, discussed DMT, how it differs from other psychedelic medicines, and what the future holds for DMT-assisted treatments.


She spoke about the benefits of DMT, what the treatment targets are, and early research of the drug.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Tired scared retiree man holding chest with anginal symptoms, pallor and diaphoresis at home. Suffering male with cardiac origin pain, prexcordial pressure, arrhythmia risk, urgent medical attention - Image credit: DimaBerlin | stock.adobe.com
Image credit: Sebastian Kaulitzki | stock.adobe.com
Magnified bone marrow biopsy showing plasma cells with irregular nuclei and multiple myeloma tumor cells infiltrating normal hematopoietic tissue
Health and nutrition: the role of glp-1 in diabetes management with apple and syringe - Image credit: Thanayut | stock.adobe.com
Image credit: Dr_Microbe | stock.adobe.com
Image credit: K KStock | stock.adobe.com
Related Content
Effects and treatment of statins concept photo. Open packaging with drugs tablets, on which is written "Statin Medication", lies near stethoscope, result analysis on cholesterol (lipid panel) and ECG.
June 3rd 2025

Expert Q&A: Pharmacist-Led Strategies to Improve Cholesterol Management

Luke Halpern, Assistant Editor Amanda Gronniger, PharmD, CPh, BCCP
Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder
March 31st 2025

Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder

Luke Halpern, Assistant Editor
Image credit: catalin | stock.adobe.com
Published: June 3rd 2025 | Updated: June 11th 2025

ASCO 2025: Zongertinib Shows Strong Potential in HER2-Mutant NSCLC Treatment Landscape

Joshua Sabari, MD Kennedy Ferruggia, Assistant Editor
Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments
November 25th 2024

Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments

X-ray of tumor on a patient's breast -- Image credit: peterschreiber.media | stock.adobe.com
June 2nd 2025

ASCO 2025: Vepdegestrant's Efficacy and Safety in ER+/HER2- Advanced Breast Cancer

Gillian McGovern, Associate Editor Erika Hamilton, MD
Oral prescription opioids -- Image credit: steheap | stock.adobe.com
May 30th 2025

Streamlining Pain Management: Shore Medical Center's Pharmacist-Driven Opioid Conversion Initiative

Gillian McGovern, Associate Editor Elizabeth DeMarco, PharmD, BCPS